Investing.com - Financial Markets Worldwide

China Regenerative Medicine International Ltd (8158)

Hong Kong
Currency in HKD
0.970
+0.070(+7.78%)
Closed·

8158 Financial Summary

Key Ratios

P/E Ratio6.17
Price/Book4.35
Debt / Equity213.08%
Return on Equity95.98%
Dividend Yield0.00%
EBITDA6.80M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
30/04
2017
30/04
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa182.14282.941.5469.4990.62
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa41.8167.7337.6219.4257.65
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-5.861.6311.81-26.116.14
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-404.2351.834.56-107.717.75
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa152.49259.14275.91185.9135.71
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa201.1147.31158.17147.7958.87
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa-55.15111.73103.9211.7925.2
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa-176.65-122.4-0.75100.0469.98
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-399.15-3.02-12.4310.7918.3
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa326.969.27-2.59-0.26-0.62
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa67.37-1.397.32-8.342.37
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa-4.525.16-8.081.4919.37
* In Millions of HKD (except for per share items)

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
30.83M / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were China Regenerative Medicine's earnings for the latest quarter?

The China Regenerative Medicine EPS (TTM) is 0.06. China Regenerative Medicine reported sales of 30.83, net income of 0.92, and EPS of 0.00 for the latest quarter.

What was China Regenerative Medicine's net income for the latest quarter?

China Regenerative Medicine's net income for the latest quarter was 0.92.

How did China Regenerative Medicine's performance compare year-over-year in the latest quarter?

The company's revenue moved from 59.79 in the previous quarter to 30.83 in the latest quarter, and net income moved from 16.83 to 0.92 compared to the previous quarter.

What is China Regenerative Medicine's net profit margin on a TTM basis?

China Regenerative Medicine's trailing twelve months (TTM) net profit margin is 19.59%.

How does China Regenerative Medicine's debt to equity ratio compare to industry standards?

China Regenerative Medicine's total debt-to-equity ratio is 213.08%.

What is China Regenerative Medicine's return on investment on a TTM basis?

China Regenerative Medicine's trailing twelve months (TTM) return on investment (ROI) is 95.98%.

Did China Regenerative Medicine gain or lose cash last quarter?

In the latest quarter, China Regenerative Medicine's net change in cash was 20.86 million.

What were China Regenerative Medicine's total assets and liabilities in the latest quarter?

As of the latest quarter, China Regenerative Medicine reported total assets of 135.71 million and total liabilities of 58.87 million.

How has China Regenerative Medicine's total revenue grown this year?

China Regenerative Medicine's total revenue was 59.79 in the previous quarter and 30.83 in the latest quarter.

What is China Regenerative Medicine's gross margin on a TTM basis?

China Regenerative Medicine's trailing twelve months (TTM) gross margin is 63.62%.

What was China Regenerative Medicine's revenue per share for the latest quarter?

China Regenerative Medicine's revenue per share for the latest quarter was 1.79.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.